Bioactivity Comments

Patent WO2004083247 A1 which claims tregalizumab, does not provide any affinity values for tregalizumab-CD4 binding, but does contain experimental evidence of the antibody's in vitro and in vivo biological effects [4].

Selectivity at other protein targets
Key to terms and symbols		Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference CD4 Hs Antibody Binding - - - 4 ⤷ [4]